Genprex (NASDAQ:GNPX) Trading 5.3% Higher

Genprex, Inc. (NASDAQ:GNPX) shares rose 5.3% during trading on Monday . The stock traded as high as $2.72 and last traded at $2.57. Approximately 77,615 shares traded hands during trading, an increase of 15% from the average daily volume of 67,697 shares. The stock had previously closed at $2.44.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Genprex in a research note on Wednesday, April 3rd.

Genprex Stock Performance

The company’s 50-day moving average price is $3.13 and its 200 day moving average price is $6.64. The stock has a market cap of $5.40 million, a PE ratio of -0.10 and a beta of -0.54.

Hedge Funds Weigh In On Genprex

A hedge fund recently bought a new stake in Genprex stock. AMH Equity Ltd bought a new position in shares of Genprex, Inc. (NASDAQ:GNPX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 813,135 shares of the company’s stock, valued at approximately $321,000. Genprex makes up approximately 0.4% of AMH Equity Ltd’s portfolio, making the stock its 23rd largest position. AMH Equity Ltd owned about 1.37% of Genprex at the end of the most recent quarter. 14.05% of the stock is currently owned by hedge funds and other institutional investors.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.